Alzheimer's event what can you do ?

The development of the next generation of Alzheimer's disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the congress is to bring together today's worldwide leaders in the treatment of Alzheimer's disease in order to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer's disease treatments. It will also allow the participants to share their experience on the disease symptoms, and their skills on the dementia treatment. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments. The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2018 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease symptoms or even at the asymptomatic stage. New examples of trials will be highlighted in the 2019 CTAD Congress. Speeding the development of effective Alzheimer's treatment disease is one of the urge of the CTAD 2019 conference. Reviews, original research articles and short reports on Alzheimer prevention will be published in the JPAD . They will include articles on the following topics : neurosciences, biomarkers, imaging, epidemiology, public health, physical cognitive exercise, nutrition, risk and protective factors, drug development, trials design, and health economic outcomes.